Experimental infection and protection against ... - TI Pharma

236 Chapter 11
42. Korsholm KS. One does not fit all: new adjuvants are needed and vaccine
formulation is critical. Expert Rev Vaccines 2011; 10:45-48.
43. Douradinha B, Doolan DL. Harnessing immune responses against Plasmodium
for rational vaccine design. Trends Parasitol 2011; 27:274-283.
44. Nganou-Makamdop K, van Roosmalen ML, Audouy SA et al. Bacterium-like
particles as multi-epitope delivery platform for Plasmodium berghei
circumsporozoite protein induce complete protection against malaria in mice.
Malar J 2012; 11:50.
45. Moon JJ, Suh H, Polhemus ME, Ockenhouse CF, Yadava A, Irvine DJ. Antigendisplaying
lipid-enveloped PLGA nanoparticles as delivery agents for a
Plasmodium vivax malaria vaccine. PLoS One 2012; 7:e31472.
46. Hill AV, Reyes-Sandoval A, O'Hara G et al. Prime-boost vectored malaria
vaccines: progress and prospects. Hum Vaccin 2010; 6:78-83.
47. Raviprakash K, Porter KR. Needle-free injection of DNA vaccines: a brief
overview and methodology. Methods Mol Med 2006; 127:83-89.
48. Senel S, Rathbone MJ, Cansiz M, Pather I. Recent developments in buccal and
sublingual delivery systems. Expert Opin Drug Deliv 2012.
49. Mahdi Abdel HM, Remarque EJ, van Duivenvoorde LM et al. Vaccination with
Plasmodium knowlesi AMA1 formulated in the novel adjuvant co-vaccine HT
protects against blood-stage challenge in rhesus macaques. PLoS One 2011;
6:e20547.
50. Sauerwein RW, Roestenberg M, Moorthy VS. Experimental human challenge
infections can accelerate clinical malaria vaccine development. Nat Rev
Immunol 2011; 11:57-64.
51. McCall MB, Netea MG, Hermsen CC et al. Plasmodium falciparum infection
causes proinflammatory priming of human TLR responses. J Immunol 2007;
179:162-171.
52. Hermsen CC, Telgt DS, Linders EH et al. Detection of Plasmodium falciparum
malaria parasites in vivo by real-time quantitative PCR. Mol Biochem Parasitol
2001; 118:247-251.
53. Felger I, Genton B, Smith T, Tanner M, Beck HP. Molecular monitoring in
malaria vaccine trials. Trends Parasitol 2003; 19:60-63.
54. Hermsen CC, de Vlas SJ, van Gemert GJ, Telgt DS, Verhage DF, Sauerwein RW.
Testing vaccines in human experimental malaria: statistical analysis of
parasitemia measured by a quantitative real-time polymerase chain reaction.
Am J Trop Med Hyg 2004; 71:196-201.
55. Dietz K, Raddatz G, Molineaux L. Mathematical model of the first wave of
Plasmodium falciparum asexual parasitemia in non-immune and vaccinated
individuals. Am J Trop Med Hyg 2006; 75:46-55.
56. Bejon P, Andrews L, Andersen RF et al. Calculation of liver-to-blood inocula,
parasite growth rates, and preerythrocytic vaccine efficacy, from serial
quantitative polymerase chain reaction studies of volunteers challenged with
malaria sporozoites. J Infect Dis 2005; 191:619-626.